Mendelspod Podcast

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

https://mendelspod.com/

Eine durchschnittliche Folge dieses Podcasts dauert 29m. Bisher sind 448 Folge(n) erschienen. Alle 5 Tage erscheint eine Folge dieses Podcasts
subscribe
share



 

The Meteoric Rise of Twist Bioscience and the Wild Demand for DNA: Emily Leproust, CEO


In 2013 Twist Bioscience was a newcomer to a market that most of us thought was saturated, cornered, commoditized—that of synthetic DNA. But Emily Leproust and her co-founders saw something different. They saw "a big market with unhappy customers.” Today, with a radically disruptive technology, they are market dominant. Twist is a publicly traded company whose stock has doubled already once since they IPOd last year...


share





   n/a
 
 

October 2019 Review with Nathan and Laura: Prime Editing, Vertex Win, and ASHG


Our Halloween show this year summarizing October’s genomics news has more tricks and treats than spooks and scares. It’s Nathan and Laura back to sift through a big month of happenings from the cool CRISPR upgrade to Inscripta’s bold move in gene editing to Ancestry.com’s shift into health testing. It’s all here, right now, on Mendelspod.


share





   n/a
 
 

Should We Increase Panel Testing for All Breast Cancer Patients?


It’s a hot question in the field today. Recently several studies arguing for increased testing for all breast cancer patients have been published in leading oncology journals. Peter Beitsch is a breast cancer surgeon in Dallas Texas and co-author of one such study in the Journal of Clinical Oncology. He says that NCCN guidelines were created when tests were much more expensive and in an outdated context and that many patients are going under-diagnosed today.


share





   n/a
 
 

Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution


Not many people have had quite the same view on the genomics revolution as John Stuelpnagel. He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia). And he’s the Chairman of Fabric, 10X Genomics, and Inscripta. And we could say, not many have had the foresight as John. He concedes it was his perception of just how complex biology would turn out to be. John is our guest today to preview and describe what he calls the new “writing” phase of genomics...


share





   n/a
 
 

Genomics Going from a Passive to an Active Science: John Stuelpnagel on the “Write” Revolution


Not many people have had quite the same view on the genomics revolution as John Stuelpnagel. He co-founded Illumina, Ariosa, and Fabric Genomics (formerly Omicia). And he’s the Chairman of Fabric, 10X Genomics, and Inscripta. And not all had the foresight John did that biology would turn out to be so complex. John is our guest today to preview and describe what he calls the new “writing” phase of genomics, which he says is already underway.


share





   n/a
 
 

Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019


Ed Abrahams has a message for Nancy Pelosi about HR 3. That’s the new bill in the House to reduce drug pricing. Ed is the President of the Personalized Medicine Coalition, an advocacy organization in Washington representing our industry which will soon announce a new caucus in congress devoted to personalized medicine. Ed joins us today and says to Pelosi, there’s a better way, a more American way to reduce drug costs.


share





   n/a
 
 

Karen Miga on the Next Era of Genomics


"Welcome to the era of T2T genomics,” tweeted UCSC’s Karen Miga on August 16th of this year. Then she linked to a paper on bioRxiv that begins: "After nearly two decades of improvements, the current human reference genome (GRCh38) is the most accurate and complete vertebrate genome ever produced. However, no one chromosome has been finished end to end, and hundreds of unresolved gaps persist.”


share





 2019-10-08  n/a
 
 

September 2019 Review with Nathan and Laura: Same-Sex Genetics, Mosquitos, and Another DTC Scandal


After the summer break, Nathan and Laura, stir from their beach slumbers, to again offer their anything but sleepy opinions on the latest genomics headlines.


share





 2019-10-01  n/a
 
 

What Are the Treatment Implications Now that We Can See Tumor Heterogeneity? We Ask Cathy Smith, UCSF


Cathy Smith counts herself among the Gleevec Generation after the landmark targeted cancer therapy. She’s an optimist who believes in the possibilities of precision medicine. “We are outsmarting cancer,” she says. Cathy is an Assistant Professor of Hematology/Oncology at UCSF where she is also an MD treating patients. Her area of expertise is in acute myeloid leukemia or AML...


share





 2019-09-17  n/a
 
 

We Can See Tumor Heterogeneity. Now What? We Ask Cathy Smith, UCSF


Cathy Smith counts herself among the Gleevec Generation after the landmark targeted cancer therapy. She’s an optimist who believes in the possibilities of precision medicine. “We are outsmarting cancer,” she says. Cathy is an Assistant Professor of Hematology/Oncology at UCSF where she is also an MD treating patients. Her area of expertise is in acute myeloid leukemia or AML...


share





 2019-09-17  n/a